Riociguat real-world use in patients with chronic thromboembolic pulmonary hypertension: A retrospective, observational cohort study in France - 06/06/23
, Jean Dallongeville, MD b, Lionel Bensimon c, Antoinette Hakme c, Nathalie Bénard c, Laurie Lévy-bachelot c, Mathilde Pouriel d, Olivier Sitbon, MD, PhD eAbstract |
Background |
Riociguat is the first approved treatment for inoperable and persistent/recurrent post-surgery chronic thromboembolic pulmonary hypertension (CTEPH). The RetrospectIve Adempas® stuDy (RiAD) aimed to describe the real-world utilization of riociguat in France.
Methods |
In this retrospective multicentric study in patients initiating riociguat, dosing regimen, co-treatments and clinical characteristics were collected over a 2-year follow-up period.
Results |
A total of 173 patients (mean age, 71.4 years; female, 63.0%; NYHA II-III, 80.3%) were included from January 2015 to December 2016 in 18 centers. All patients were diagnosed with CTEPH (75.7% inoperable and 20.8% with persistent/recurrent pulmonary hypertension [pH] after surgery) with mean (SD) right atrial pressure 7.6 (4.2) mmHg, mean pulmonary artery pressure 43.0 (11.4) mmHg and mean cardiac output 4.1 (1.1) L/min. Before riociguat initiation, 32.4% of patients previously received at least one pH-specific therapy. At initiation, 93.1% of patients were receiving anticoagulants and 83.2% were not receiving pH-specific co-treatments. Riociguat was initiated at 1 mg three times daily (t.i.d.) in 85.5% of patients and 82.1% were receiving 2.5 mg dose t.i.d. at 24 months. The maximal daily dose of 7.5 mg was never exceeded. At 24 months, the estimated rate of patients still taking riociguat was 78.8% with an estimated mean (SD) time on treatment of 20.1 (0.5) months per patient. No new safety signals were recorded.
Conclusions |
The results of this real-world study show that riociguat is used in France in accordance with its therapeutic indication in patients with inoperable or persistent/recurrent post-operative CTEPH and confirm its long-term safety.
Le texte complet de cet article est disponible en PDF.Keywords : Pulmonary embolism, Pulmonary hypertension, Soluble guanylate cyclase, Riociguat, Real-world data
Abbreviations : 6MWD, AE, BNP, BPA, cGMP, CO, CTEPH, ERA, mPAP, NO, NT-proBNP, NYHA, PA, PAP, PAWP, PDE5i, PE, PEA, PH, PVR, RAP, SAE, sGC, t.i.d.
Plan
Vol 83
Article 100987- juin 2023 Retour au numéro
Article précédent
- Reduced peak expiratory flow predicts increased risk of cardiovascular disease: A 10-year prospective cohort study in Eastern China
- Yerui Zhang, Cheng Cheng, Fang Wei, Zhenguo Wu, Huiliang Cui, Li Liu, Fanghong Lu, Jie Peng, Jianmin Yang
- Stereotactic body radiation therapy (SBRT) as salvage treatment for early stage lung cancer with interstitial lung disease (ILD): An observational and exploratory case series of non-asian patients
- J. Pluvy, A. Zaccariotto, P. Habert, J. Bermudez, A. Mogenet, J.Y. Gaubert, P. Tomasini, L. Padovani, L. Greillier
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?